Renaissance Technologies LLC Sells 105,700 Shares of LifeStance Health Group, Inc. (NASDAQ:LFST)

Renaissance Technologies LLC lessened its stake in LifeStance Health Group, Inc. (NASDAQ:LFST) by 40.5% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 155,000 shares of the company’s stock after selling 105,700 shares during the quarter. Renaissance Technologies LLC’s holdings in LifeStance Health Group were worth $761,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its stake in shares of LifeStance Health Group by 82.0% during the second quarter. Dimensional Fund Advisors LP now owns 1,016,452 shares of the company’s stock valued at $4,991,000 after purchasing an additional 457,930 shares during the last quarter. TD Asset Management Inc acquired a new stake in shares of LifeStance Health Group in the 2nd quarter valued at $623,000. Vanguard Group Inc. raised its position in shares of LifeStance Health Group by 1.3% during the first quarter. Vanguard Group Inc. now owns 7,668,966 shares of the company’s stock worth $47,318,000 after acquiring an additional 95,197 shares during the last quarter. GSA Capital Partners LLP raised its position in shares of LifeStance Health Group by 161.6% during the first quarter. GSA Capital Partners LLP now owns 69,492 shares of the company’s stock worth $429,000 after acquiring an additional 42,932 shares during the last quarter. Finally, Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group during the first quarter valued at $238,000. 85.50% of the stock is owned by institutional investors.

Insider Buying and Selling

In other LifeStance Health Group news, insider Ann Varanakis sold 5,269 shares of the business’s stock in a transaction dated Friday, August 23rd. The stock was sold at an average price of $6.28, for a total value of $33,089.32. Following the completion of the transaction, the insider now directly owns 263,007 shares of the company’s stock, valued at approximately $1,651,683.96. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 6.60% of the stock is currently owned by company insiders.

LifeStance Health Group Stock Performance

Shares of NASDAQ:LFST opened at $6.82 on Wednesday. The firm’s 50 day simple moving average is $6.36 and its 200 day simple moving average is $6.04. LifeStance Health Group, Inc. has a fifty-two week low of $4.64 and a fifty-two week high of $9.20. The company has a market capitalization of $2.61 billion, a price-to-earnings ratio of -14.21 and a beta of 1.24. The company has a debt-to-equity ratio of 0.20, a current ratio of 1.22 and a quick ratio of 1.22.

LifeStance Health Group (NASDAQ:LFST) last posted its earnings results on Thursday, August 8th. The company reported ($0.06) earnings per share for the quarter, topping the consensus estimate of ($0.07) by $0.01. The company had revenue of $312.30 million for the quarter, compared to analyst estimates of $305.85 million. LifeStance Health Group had a negative net margin of 13.05% and a negative return on equity of 10.51%. The business’s revenue for the quarter was up 20.3% compared to the same quarter last year. During the same period last year, the business posted ($0.13) earnings per share. As a group, sell-side analysts forecast that LifeStance Health Group, Inc. will post -0.24 earnings per share for the current year.

Analysts Set New Price Targets

A number of analysts recently commented on LFST shares. UBS Group lowered their price objective on LifeStance Health Group from $9.00 to $7.50 and set a “neutral” rating for the company in a research report on Thursday, August 15th. Barclays lowered their target price on shares of LifeStance Health Group from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Friday, August 9th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $8.25.

About LifeStance Health Group

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.